CLINICAL_TRIALS
trial_result
· 2023-08-23
Clinical Trial Update: Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study [Phase 2]
Summary
Phase 2 dose-finding trial of olpasiran evaluating lipoprotein(a) reduction and cardiovascular event outcomes, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Cardiovascular Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-08-23